The management of thoracic disease is changing rapidly. As we continue to gain understanding of the pathophysiology and underlying molecular basis of these conditions, we are faced with more management options, including targeted therapy (its definition is also rapidly evolving), catheter-based treatments, minimally invasive surgery, and all forms of novel radiotherapy, just to mention a few. Every treatment choice has its challenges in achieving precision, reaching its target, delivering the needed therapy and effectively executing the treatment, preferably all performed with minimal morbidity and invasiveness to the patient. It can also be foreseen that perhaps many of these treatments in the future may be administered in combination.
This supplement issue will be divided into parts 1 and 2, based on the Asia Thoracic Cancer Care Summit (ATCCS) 2018 hosted by The Chinese University of Hong Kong. The summit gathers together 17 world renowned overseas faculties, as well as seven local experts in thoracic cancer care management in sharing their experience, latest knowledge and research. It is hoped that such cross specialty bonding will allow challenges to be overcome through closer collaboration and innovation, ultimately to improve patient care.